Clinical, endoscopic and histopathological evaluation of the efficacy of budesonide in the treatment of inflammatory bowel disease in dogs

• Autorzy: Rychlik A. , Kolodziejska-Sawerska A. , Nowicki M. , Szweda M.
• Języki publikacji: EN

Abstrakty

EN

This study evaluates the efficacy of budesonide in the treatment of inflammatory bowel disease (IBD) in dogs based on the results of clinical, endoscopic and histopathological examinations. The severity of clinical symptoms was assessed based on CIBDAI scores, and macroscopic and histopathological changes were described in accordance with the recommendations of the WSAVA Gastrointestinal Standardization Group for 2008. The results of the experiment revealed that budesonide does not offer effective treatment for canine IBD. The tested drug failed to alleviate the clinical symptoms of disease, lower CIBDAI scores, or improve the macroscopic appearance of intestinal mucosa. The effectiveness of budesonide was most highly evaluated in the histopathological picture of duodenal, jejunal and colonic mucosa.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2016
• Tom: 19
• Numer: 1
• Opis fizyczny: p.159-164,ref.

Twórcy

autor

Rychlik A.

• Department of Clinical Diagnostics, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn, Poland

autor

Kolodziejska-Sawerska A.

• Department of Clinical Diagnostics, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn, Poland

autor

Nowicki M.

• Department of Clinical Diagnostics, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn, Poland

autor

Szweda M.

• Department of Clinical Diagnostics, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn, Poland

Bibliografia

• Angelucci E, Malesci A, Danese S (2008) Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Curr Med Chem 15: 2527-2535.
• Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, Eliakim R, Maoz E, Mittmann U (1998) Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 115: 835-840.
• Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG (1997) Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 41: 209-214.
• Craven M, Simpson JW, Ridyard AE, Chandler ML (2004) Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). J Small Anim Pract 45: 336-342.
• Day MJ, Blizer T, Mansell J, Wilcock B, Hall EJ, Jergens A, Minami T, Willard M, Washabau R (2008) Histopathological standards for the diagnosis of gastrointestinal inflammation in endoscopic biopsy samples from the dog and cat: a report from the World Small Animal Veterinary Association Gastrointestinal Standardization Group. J Comp Pathol 138 (Suppl 1): S1-S43.
• Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J (1996) Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 8: 905-909.
• Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, Benson TJ, Evans R (2003) A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 17: 291-297.
• Jergens AE, Simpson KW (2012) Inflammatory bowel disease in veterinary medicine. Front Biosci (Elite Ed) 4: 1404-1419.
• Malewska K, Rychlik A, Nieradka R, Kander M (2011) Treatment of inflammatory bowel disease (IBD) in dogs and cats. Pol J Vet Sci 14: 165-171.
• Otley A, Steinhart AH (2005) Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 4: CD000296.
• Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L (2000) Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther 14: 1419-1428.
• Pietra M, Fracassi F, Diana A, Gazzotti T, Bettini G, Peli A, Morini M, Pagliuca G, Roncada P (2013) Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. Am J Vet Res 74: 78-83.
• Rutgeerts P, Lo¨fberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H (1994) A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 331: 842-845.
• Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH (2008) Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 3: CD000296.
• Simms L, Steinhart AH (2001) Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 1: CD002913.
• Simpson KW, Jergens AE (2011) Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Vet Clin North Am Small Anim Pract 41: 381-398.
• Tumulty JW, Broussard JD, Steiner JM, Peterson ME, Williams DA (2004) Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. J Am Anim Hosp Assoc 40: 120-123.

Identyfikatory

DOI

10.1515/pjvs-2016-0020